antibodies -online.com





anti-CLEC2A antibody (N-Term)



Image



Go to Product page

_					
U	V	er	VI	е	W

Overview		
Quantity:	0.1 mg	
Target:	CLEC2A	
Binding Specificity:	N-Term	
Reactivity:	Human	
Host:	Rabbit	
Clonality:	Polyclonal	
Conjugate:	This CLEC2A antibody is un-conjugated	
Application:	Western Blotting (WB), Enzyme Immunoassay (EIA), Immunofluorescence (IF)	
Product Details		
Immunogen:	16 amino acid synthetic peptide near the amino terminus of Human CLEC2A	
Isotype:	IgG	
Purification:	Affinity chromatography purified via peptide column	
Target Details		
Target:	CLEC2A	
Alternative Name:	CLEC2A (CLEC2A Products)	
Background:	CLEC2A (C-type lectin domain family 2 member A), also known as PILAR (proliferation-induced	
	lymphocyte-associated receptor) is involved in modulating T-cell expansion. It is a 32 kDa	
	single-pass type II membrane protein that contains one C-type lectin domain in its extracellular	
	region and belongs to the CTL/CTLD superfamily. CLEC2A is mainly expressed in skin and	


Target Details

	highly expressed in CD8(+), B lymphocytes and naive CD4(+) T cells. Manipulation of CLEC2A
	signaling may be important for treatment of autoimmune diseases and cancer. Synonyms: C-
	type lectin domain family 2 member A, KACL, Keratinocyte-associated C-type lectin, PILAR,
	Proliferation-induced lymphocyte-associated receptor, UNQ579
Gene ID:	387836
NCBI Accession:	NP_001124183

Application Details

Application Notes:	Optimal working dilution should be determined by the investigator.
Restrictions:	For Research Use only
Handling	
Concentration:	1.0 mg/mL

Buffer:	PBS containing 0.02 % Sodium Azide as preservative
Preservative:	Sodium azide
Precaution of Use:	This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice:	Avoid repeated freezing and thawing.
Storage:	4 °C/-20 °C



Western Blotting

Image 1. Western blot analysis of CLEC2A in K562 cell lysate with CLEC2A Antibody at 1 ug/ml in (A) the absence and (B) the presence of blocking peptide.